Status:
COMPLETED
The Study of HIV Protease Inhibitors and Their Effects on Glucose Metabolism
Lead Sponsor:
US Department of Veterans Affairs
Conditions:
Diabetes
HIV Infections
Eligibility:
All Genders
18-72 years
Brief Summary
The purpose of this study is to determine the mechanisms by which HIV protease inhibitors contribute to the development of diabetes in HIV-infected patients. The investigators propose that some HIV pr...
Detailed Description
HIV protease inhibitors (PIs) have been associated with type 2 diabetes. To design future HIV drugs that have have the least adverse metabolic effects, it is necessary to identify the disorders of glu...
Eligibility Criteria
Inclusion
- Healthy, HIV-negative volunteers between the ages of 18-72 years
Exclusion
- Any subject with states known to be associated with insulin resistance, such as impaired fasting glucose (glucose \> 110 mg/dl), overweight (body mass index \[BMI\] \> 27), dyslipidemia (triglycerides \> 150 mg/dl), hypertension (blood pressure \[BP\] \> 130/85 mmHg or on medication), renal disease, systemic use of glucocorticoids, growth hormone, niacin, or antipsychotics.
- Women will be tested for pregnancy immediately prior to study and excluded if pregnant.
Key Trial Info
Start Date :
January 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2008
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00259727
Start Date
January 1 2006
End Date
September 1 2008
Last Update
September 30 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VA Medical Center, San Francisco
San Francisco, California, United States, 94121